|
Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume. |
|
|
Employment - Genomic Health (I) |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Exact Sciences; Ferring; Janssen Biotech; Merck; Myovant Sciences; Pfizer; Sanofi |
Speakers' Bureau - AstraZeneca; Sanofi |
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst) |
Travel, Accommodations, Expenses - Sanofi |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Insmed; Revance Therapeutics; Veru |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - BioNano Genomics; Recursion Pharmaceuticals; Sesen Bio; Soligenix; Tonix Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Stock and Other Ownership Interests - Myovant Sciences |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Blue Earth Diagnostics (Inst); Delfi Diagnostics (Inst); Diasorin (Inst); Exact Sciences (Inst); Ferring (Inst); Guardant Health (Inst); Janssen (Inst); LungLife AI (Inst); MDxHealth (Inst); Merck (Inst); Myriad Genetics (Inst); Pfizer (Inst); Photocure (Inst); Sanofi (Inst) |
|
|
Employment - Astellas Pharma |
Research Funding - Astellas Pharma |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Pfizer |
|
|
|
|
|
No Relationships to Disclose |